| Date | Title | | | 07/29/10 | Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease| CARLSBAD, Calif., July 29, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE: GSK) related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the option to license it.
"We are pleased to have achieved this milestone so early in our collaboration... |
|  | | 07/26/10 | Webcast Alert: Isis Pharmaceuticals' Second Quarter 2010 Financial Results Conference Call| CARLSBAD, Calif., July 26, 2010 /PRNewswire via COMTEX/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Second Quarter 2010 Financial Results
When: Monday, August 9, 2010 at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live on the Internet. Simply log onto our Web site
listed above.
Contacts: Kristina Lemonidis
Director, Investor Relations
... |
| | | 06/29/10 | Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions| ORLANDO, Fla. and CARLSBAD, Calif., June 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS - News) announced today that data from seven programs in Isis' broad metabolic disease franchise were presented at the American Diabetes Association's (ADA) 70th Scientific Sessions in Orlando. These presentations included two oral talks highlighting data from Isis' Phase 2 study of ISIS 113715 in patients with type 2 diabetes and Isis' Phase 1 study of ISIS-GCGRRx. Isis and collab... |
| | | 06/22/10 | Isis and Alnylam Provide Update on Regulus' Strategic Alliance with Sanofi-Aventis| Press Release Source: Alnylam Pharmaceuticals, Inc. On Tuesday June 22, 2010, 6:05 am
CAMBRIDGE, Mass. and CARLSBAD, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News):
New Partnership Validates Alnylam and Isis Strategy for Shareholder Value Creation
Regulus, Alnylam and Isis to Host Conference Call Webcast to Discuss Regulus-Sanofi-aventis Collaboration on June 22, 2010 at 8:30 a.m. ET (5:30 a.m. PT)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News) and Is... |
| |
|
